Summary of experimental parameters for determining the frequency of CRU in recipients of Slug−/− or Slug+/− BM cells
| Cell dose injected . | No. positive . | No. analyzed . |
|---|---|---|
| Slug+/− | ||
| 50 000 | 1 | 12 |
| 200 000 | 9 | 11 |
| 1 000 000 | 12 | 12 |
| CRU frequency (95% CI) | 1/166 810 (1/301 315-1/92 347) | |
| Slug−/− | ||
| 50 000 | 10 | 11 |
| 200 000 | 10 | 10 |
| 1 000 000 | 11 | 11 |
| CRU frequency (95% CI) | 1/20 830 (1/45 249-1/9589) |
| Cell dose injected . | No. positive . | No. analyzed . |
|---|---|---|
| Slug+/− | ||
| 50 000 | 1 | 12 |
| 200 000 | 9 | 11 |
| 1 000 000 | 12 | 12 |
| CRU frequency (95% CI) | 1/166 810 (1/301 315-1/92 347) | |
| Slug−/− | ||
| 50 000 | 10 | 11 |
| 200 000 | 10 | 10 |
| 1 000 000 | 11 | 11 |
| CRU frequency (95% CI) | 1/20 830 (1/45 249-1/9589) |
Irradiated CD45.1+ recipients (8-10 mice per cell dose) were injected with 3 doses of test BM cells from Slug−/− or Slug+/− control mice, together with a constant dose (2 × 105) of wild-type competitor cells (CD45.1+/CD45.2+). At 16 weeks after BM transplantation, test BM cell-derived contributions in chimerism were determined by monitoring the percentage of CD3e, B220, and Mac-1/Gr-1 cells among total donor (test and competitor) cell-derived cells in peripheral blood. A mouse reconstituted to 1% or more of test cell-derived T or B lymphoid cells and 1% or more of test cell-derived myeloid cells was scored as positive. P < .001 for Slug−/− vs Slug+/− control mice.